JP7123932B2 - 神経保護及び神経疾患におけるｃｇｒｐ受容体アンタゴニストの使用 - Google Patents

神経保護及び神経疾患におけるｃｇｒｐ受容体アンタゴニストの使用 Download PDF

Info

Publication number
JP7123932B2
JP7123932B2 JP2019533291A JP2019533291A JP7123932B2 JP 7123932 B2 JP7123932 B2 JP 7123932B2 JP 2019533291 A JP2019533291 A JP 2019533291A JP 2019533291 A JP2019533291 A JP 2019533291A JP 7123932 B2 JP7123932 B2 JP 7123932B2
Authority
JP
Japan
Prior art keywords
leu
ala
arg
thr
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019533291A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019530741A5 (https=
JP2019530741A (ja
Inventor
クリストファー ジェイ． ソアレス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2019530741A publication Critical patent/JP2019530741A/ja
Publication of JP2019530741A5 publication Critical patent/JP2019530741A5/ja
Priority to JP2022105144A priority Critical patent/JP2022126857A/ja
Application granted granted Critical
Publication of JP7123932B2 publication Critical patent/JP7123932B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57527—Calcitonin gene related peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
JP2019533291A 2016-09-02 2017-08-30 神経保護及び神経疾患におけるｃｇｒｐ受容体アンタゴニストの使用 Active JP7123932B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022105144A JP2022126857A (ja) 2016-09-02 2022-06-29 医薬組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662383334P 2016-09-02 2016-09-02
US62/383,334 2016-09-02
PCT/US2017/049460 WO2018045083A1 (en) 2016-09-02 2017-08-30 Use of cgrp receptor antagonists in neuroprotection and neurological disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022105144A Division JP2022126857A (ja) 2016-09-02 2022-06-29 医薬組成物

Publications (3)

Publication Number Publication Date
JP2019530741A JP2019530741A (ja) 2019-10-24
JP2019530741A5 JP2019530741A5 (https=) 2020-10-08
JP7123932B2 true JP7123932B2 (ja) 2022-08-23

Family

ID=59914517

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019533291A Active JP7123932B2 (ja) 2016-09-02 2017-08-30 神経保護及び神経疾患におけるｃｇｒｐ受容体アンタゴニストの使用
JP2022105144A Pending JP2022126857A (ja) 2016-09-02 2022-06-29 医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022105144A Pending JP2022126857A (ja) 2016-09-02 2022-06-29 医薬組成物

Country Status (10)

Country Link
US (2) US11390654B2 (https=)
EP (2) EP4316595A3 (https=)
JP (2) JP7123932B2 (https=)
KR (1) KR102657418B1 (https=)
CN (1) CN109922820A (https=)
AU (1) AU2017319512A1 (https=)
CA (1) CA3035561A1 (https=)
ES (1) ES2965087T3 (https=)
IL (1) IL265099B2 (https=)
WO (1) WO2018045083A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4316595A3 (en) 2016-09-02 2024-04-17 Christopher J. Soares Use of cgrp receptor antagonists in treating glaucoma
EP3893918B1 (en) * 2018-12-10 2024-09-25 Rigshospitalet Vasodilators for use in the treatment of a retinal ischemic disorder
CN118717761A (zh) * 2024-05-27 2024-10-01 复旦大学 瑞美吉泮在制备治疗/预防阿尔茨海默病药物中的应用
CN119524110B (zh) * 2024-12-16 2026-03-20 中国人民解放军军事科学院军事医学研究院 Cgrp在减轻植入式神经电极免疫排斥中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015511581A (ja) 2012-02-27 2015-04-20 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｎ−（５Ｓ，６Ｓ，９Ｒ）−５−アミノ−６−（２，３−ジフルオロフェニル）−６，７，８，９−テトラヒドロ−５Ｈ−シクロヘプタ［ｂ］ピリジン−９−イル−４−（２−オキソ−２，３−ジヒドロ−１Ｈ−イミダゾ［４，５−ｂ］ピリジン−１−イル）ピペリジン−１−カルボキシレート塩
JP2015513318A (ja) 2012-01-26 2015-05-07 クリストファー ジェイ． ソアレス ペプチドホルモンのカルシトニンｃｇｒｐファミリーのペプチドアンタゴニスト及びその使用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
NO812612L (no) 1980-08-06 1982-02-08 Ferring Pharma Ltd Enzym-inhibitorer.
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
CH657779A5 (de) 1982-10-05 1986-09-30 Sandoz Ag Galenische zusammensetzungen enthaltend calcitonin.
IT1164225B (it) 1983-05-13 1987-04-08 Anic Spa Analoghi retro-invertiti del pentapeptide potenziante la bradichina bpp5a e metodi per la loro preparazione
US4530838A (en) 1983-07-08 1985-07-23 The Salk Institute For Biological Studies Synthetic calcitonin-gene-related peptides for lowering blood pressure or gastric acid secretion in mammals
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
JPS62129297A (ja) 1985-08-09 1987-06-11 Toyo Jozo Co Ltd カルシトニン遺伝子関連ペプチド誘導体
JPS62231168A (ja) 1986-03-21 1987-10-09 ハイブリテツク・インコ−ポレイテツド アナライト−レセプタ−分析用内部標準を設けるための改良法
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
ES2181691T5 (es) 1992-06-11 2007-10-01 Alkermes Controlled Therapeutics, Inc. Sistema de distribucion de proteina eritropoyetina.
US5354934A (en) 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
WO1994021665A1 (en) 1993-03-24 1994-09-29 Amylin Pharmaceuticals, Inc. Cloned receptors and methods for screening
US5698401A (en) 1995-11-14 1997-12-16 Abbott Laboratories Use of nuclear magnetic resonance to identify ligands to target biomolecules
WO1997041223A1 (en) * 1996-04-15 1997-11-06 The University Of Miami Molecular clone of cgrp receptor component protein and uses thereof
PT1248643E (pt) * 2000-01-20 2005-10-31 Yeda Res & Dev Utilizacao de copolimero 1 e peptidos e polipeptidos congeneres e de celulas t tratadas co estes compostos para terapia neuroprotectora
US20050054557A1 (en) 2002-05-09 2005-03-10 Goldberg Michael M. Compositions for delivering parathyroid hormone and calcitonin
PT1534313E (pt) * 2002-07-30 2013-01-25 Omeros Corp Soluções e método de irrigação oftalmológica
US7812120B2 (en) 2003-03-21 2010-10-12 Par Pharmaceutical, Inc. Nasal calcitonin formulations containing chlorobutanol
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
RU2385878C2 (ru) 2004-02-11 2010-04-10 Амилин Фармасьютикалз, Инк. Пептид, обладающий свойствами амилина (варианты), и его применение (варианты)
EP1718665B1 (en) * 2004-02-11 2013-04-10 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
EP2286840A3 (en) 2004-11-01 2013-09-04 Amylin Pharmaceuticals, LLC Treatment of obesity and related diseases
WO2007055728A1 (en) 2005-11-01 2007-05-18 Amylin Pharmaceuticals, Inc. Treatment of obesity and related disorders
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
BRPI0606992A2 (pt) 2005-02-11 2009-07-28 Amylin Pharmaceuticals Inc análogo e polipeptìdeos hìbridos de gip com propriedades selecionáveis
EP2258382A3 (en) 2005-03-31 2014-05-14 Amylin Pharmaceuticals, LLC Amylin and amylin agonists for treating psychiatric diseases and disorders
WO2007055743A2 (en) 2005-11-01 2007-05-18 Amylin Pharmaceuticals, Inc. Treatment of obesity and related disorders
MY153249A (en) 2005-11-14 2015-01-29 Rinat Neuroscience Corp Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
KR20100098628A (ko) 2007-11-14 2010-09-08 아밀린 파마슈티칼스, 인크. 비만 및 비만 관련 질환 및 장애의 치료 방법
WO2009094172A2 (en) * 2008-01-22 2009-07-30 Araim Pharmaceuticals, Inc. Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
US8748375B2 (en) 2009-03-17 2014-06-10 Amylin Pharmaceuticals, Llc Methods for affecting body composition using amylin agonists
US20150031623A1 (en) 2011-09-29 2015-01-29 Mcw Research Foundation, Inc. Thrombopoietin receptor ligands for neuroprotection
US20140249076A1 (en) 2011-10-18 2014-09-04 Astrazeneca Pharmaceuticals Lp Amylin-calcitonin chimeric peptides conjugated to duration enhancing moieties
WO2015176017A1 (en) * 2014-05-16 2015-11-19 Salk Institute For Biological Studies Compositions and methods for treating metabolic disorders
EP4316595A3 (en) 2016-09-02 2024-04-17 Christopher J. Soares Use of cgrp receptor antagonists in treating glaucoma

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015513318A (ja) 2012-01-26 2015-05-07 クリストファー ジェイ． ソアレス ペプチドホルモンのカルシトニンｃｇｒｐファミリーのペプチドアンタゴニスト及びその使用
JP2015511581A (ja) 2012-02-27 2015-04-20 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｎ−（５Ｓ，６Ｓ，９Ｒ）−５−アミノ−６−（２，３−ジフルオロフェニル）−６，７，８，９−テトラヒドロ−５Ｈ−シクロヘプタ［ｂ］ピリジン−９−イル−４−（２−オキソ−２，３−ジヒドロ−１Ｈ−イミダゾ［４，５−ｂ］ピリジン−１−イル）ピペリジン−１−カルボキシレート塩

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Drug Discov. Today Ther. Strateg., 2006, Vol.3, No.4, pp.593-597
The Journal of Neuroscience, 2005, Vol.25, pp.5877-5883
日本薬理学雑誌, 2012, Vol.140，pp.8-13

Also Published As

Publication number Publication date
EP3506925B1 (en) 2023-09-06
AU2017319512A1 (en) 2019-03-21
EP3506925C0 (en) 2023-09-06
US20230212248A1 (en) 2023-07-06
JP2022126857A (ja) 2022-08-30
KR20190044665A (ko) 2019-04-30
CA3035561A1 (en) 2018-03-08
EP4316595A3 (en) 2024-04-17
CN109922820A (zh) 2019-06-21
KR102657418B1 (ko) 2024-04-15
US20200165305A1 (en) 2020-05-28
WO2018045083A1 (en) 2018-03-08
EP4316595A2 (en) 2024-02-07
IL265099A (en) 2019-04-30
US12103951B2 (en) 2024-10-01
IL265099B2 (en) 2024-09-01
JP2019530741A (ja) 2019-10-24
EP3506925A1 (en) 2019-07-10
US11390654B2 (en) 2022-07-19
IL265099B1 (en) 2024-05-01
AU2017319512A2 (en) 2019-07-11
ES2965087T3 (es) 2024-04-10

Similar Documents

Publication Publication Date Title
JP2022126857A (ja) 医薬組成物
Benson et al. A novel anticonvulsant mechanism via inhibition of complement receptor C5ar1 in murine epilepsy models
US20090281522A1 (en) Methods of inhibiting seizure in a subject
US12329756B2 (en) Regulation of eIF4E activity for migraine therapy
US10919939B2 (en) Mu opioid receptor agonist analogs of the endomorphins
Ruan et al. Adrenoceptors in the eye–physiological and pathophysiological relevance
Xie et al. Long-term neuropeptide Y administration in the periphery induces abnormal baroreflex sensitivity and obesity in rats
JP6262661B2 (ja) 筋萎縮性側索硬化症治療剤
US20190002517A1 (en) Neuropeptide y-derived peptides
US20070276024A1 (en) Methods for Treating Diseases and Conditions with Inverse Agonists and for Screening for Agents Acting as Inverse Agonists
HK40008689A (en) Use of cgrp receptor antagonists in neuroprotection and neurological disorders
Wilson et al. Allergic lung inflammation affects central noradrenergic control of cholinergic outflow to the airways in ferrets
WO2012170452A2 (en) Compositions and methods for treating neurodegenerative diseases
Samsam et al. Role of neuropeptides in migraine: where do they stand in the latest expert recommendations in migraine treatment?
Stucky SEX DIFFERENCES IN GENE EXPRESSION AND PAIN-RELATED BEHAVIORS IN A PRECLINICAL MODEL OF MIGRAINE
WO2008062296A2 (en) Nop receptor agonists for the treatment of l-dopa induced dyskinesias
Class et al. Patent application title: NEUROPEPTIDE Y-DERIVED PEPTIDES Inventors: David Paul D. Woldbye (CopenhagenØ, DK) Casper Rene Gøtzsche (Copenhagen Ø, DK) Kristian Klemp (Charlottenlund, DK) Vladimir Berezin (Copenhagen N, DK) Vladimir Berezin (Copenhagen N, DK) Elisabeth Bock (Charlottenlund, DK)
Lina et al. TX, USA bDepartment of Biology and Biochemistry, University of Houston, Houston, TX, USA cDepartment of Pediatrics, University of Texas, Southwestern Medical Center, Dallas, TX, USA
Woodruff et al. A novel anticonvulsant mechanism via inhibition of complement receptor C5ar1 in murine epilepsy models
Parra et al. Changes in beta 2-adrenoceptor and other signaling proteins produced by chronic administration of'beta-blockers' in a murine asthma model

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200825

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200825

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210817

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211116

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220329

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220629

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220712

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220810

R150 Certificate of patent or registration of utility model

Ref document number: 7123932

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250